Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Changing treatment news

Show

From To
ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks

SWORD studies demonstrate long-term durable efficacy and tolerability of Juluca, the first complete 2-drug regimen, for the treatment of virologically suppressed adults with HIV

Published
05 April 2019
From
ViiV press release
Dolutegravir-based second-line ART achieves excellent virological outcomes even in the presence of resistance to recycled NRTIs

Virological response rates were excellent among patients receiving second-line antiretroviral therapy (ART) based on dolutegravir, even when regimens included a nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) to which there

Published
13 March 2019
By
Michael Carter
Early ART in HIV Possible Key to Dolutegravir Monotherapy Success

Several randomized controlled trials have shown dolutegravir monotherapy to be inferior to cART. These dolutegravir monotherapy trials, however, have been conducted in patients initiating cART during chronic rather than primary HIV infection. Since patients who start cART during the early phase of HIV infection show a reduced HIV reservoir and low viral diversity, the researchers evaluated whether these properties would allow for sustained virologic suppression after a switch to dolutegravir monotherapy.

Published
15 February 2019
From
Infectious Disease Advisor
FDA To Consider Pifeltro, Delstrigo as HIV Switch-On Therapies

The FDA will decide this year whether the once-daily Merck therapies can be marketed as a switch-on drug for patients with suppressed HIV-1.

Published
23 January 2019
From
MD Magazine
Atripla or efavirenz plus Truvada failed one in 16 people in first year

Although analyses of the failure rate of ART have been conducted before, a new analysis is the first to compute these rates for a single-drug regimen

Published
21 January 2019
By
Gus Cairns
Dolutegravir Monotherapy for HIV No Longer Recommended

Dolutegravir monotherapy should no longer be used as HIV maintenance therapy, according to Bart J.A. Rijnders, MD, PhD, and Casper Rokx, MD, PhD, both from Erasmus Medical Center, Rotterdam, the Netherlands.

Published
09 January 2019
From
Contagion Live
South Africa reports successful third-line HIV treatment programme

People with resistance to first- and second-line antiretroviral drugs can still achieve high rates of viral suppression in the first year on third-line regimens according to a

Published
04 January 2019
By
Esther Nakkazi
Dual HIV Regimen Equaled Triple Even After Treatment Failure

A "dual" combination of raltegravir (Isentress) plus boosted protease inhibitor was comparable to triple combination regimens with raltegravir for HIV in treatment-experienced patients, including those with previous treatment failure, in a retrospective study with real-world cohort.

Published
26 November 2018
From
MD Magazine
Dolutegravir plus darunavir maintains viral suppression without NRTIs

A dual antiretroviral regimen containing dolutegravir (Tivicay) and boosted darunavir (Prezista) maintains viral suppression in most people who switch from a suppressive three-drug regimen, according to an observational

Published
06 November 2018
By
Liz Highleyman
Two-drug protease inhibitor treatment as effective as three-drug treatment – and fewer stop due to side-effects

Antiretroviral treatment with a boosted protease inhibitor and one other drug is just as effective as three-drug antiretroviral therapy containing a boosted protease inhibitor but results in

Published
30 October 2018
By
Keith Alcorn
← First12345...30Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.